Key Highlights
- Paul Kim appointed as CEO of Matica Biotechnology, Inc., a leading CDMO in cell and gene therapy (CGT) manufacturing.
- Kim to drive strategic expansion in the U.S. and Korea, leveraging nearly 30 years of biopharma sector experience.
- Matica Bio to enhance board capacity and continue innovations in CGT manufacturing, following the launch of MatiMax™ cell line.
Source: Business Wire
Notable Quote
- “Together with the deep scientific expertise in-house, I look forward to propelling Matica Bio forward in the rapidly changing CGT industry.” – Paul Kim, CEO at Matica Biotechnology, Inc
SoH's Take
The appointment of Paul Kim as CEO of Matica Biotechnology, Inc. marks a significant step forward for the company in the competitive cell and gene therapy manufacturing industry. Kim’s extensive background across the CDMO, CRO, and R&D sectors of biopharma, combined with his experience in leading innovative biotech investments in Asia, positions him uniquely to lead Matica Bio’s expansion and innovation efforts. His vision for leveraging the company’s bespoke CGT manufacturing capabilities and the strategic enhancements planned for the company’s board and operational capacities indicate a robust growth trajectory ahead. This move underscores Matica Bio’s commitment to staying at the forefront of CGT manufacturing, emphasizing the importance of leadership with a deep understanding of the industry’s dynamic nature and the technological advancements required to lead in this space.
